Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2017-07-06 Capital/Financing Update
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Capital/Financing Update Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and specifically reports on the "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE" (Semi-annual review of the liquidity contract) as of June 30, 2017. This is a periodic update concerning financial arrangements (liquidity contract status) but is presented as a short press release, not a comprehensive financial report like a 10-K or IR. It details the holdings (shares and cash) under the contract compared to the previous period (Dec 31, 2016). While it relates to capital/financing, the core function here is a required periodic disclosure about a specific financial mechanism, often released via regulatory channels. Given the options, this type of periodic, non-comprehensive financial disclosure, especially one related to market stabilization/liquidity, fits best under a general regulatory announcement category. Since it is not a full Interim Report (IR), Earnings Release (ER), or a specific Capital/Financing Update (CAP) detailing a new fundraising round, the most appropriate general category for a mandatory, periodic regulatory disclosure that doesn't fit elsewhere is Regulatory Filings (RNS). It is too specific for RNS, but it is a periodic financial disclosure. However, looking closely at the definitions, it is a report on a financial arrangement. It is not a dividend notice (DIV), a major shareholding notification (MRQ), or a transaction in own shares (POS) in the sense of a buyback program execution, but rather a status report on a liquidity agreement. Given its nature as a required periodic update on a financial contract, and its format as a press release, it is closest to a general regulatory filing (RNS) or potentially a Capital/Financing Update (CAP) if the liquidity contract is viewed as part of capital management. Since it is a mandated periodic report on a financial instrument, RNS is the safest fallback for non-standard disclosures. However, since it is a report on the status of a liquidity contract, which is a financial mechanism, and it is a 'Bilan Semestriel' (Semi-annual report), it is a periodic financial disclosure. It is not a comprehensive Interim Report (IR). Given the options, RNS (Regulatory Filings) is the best fit for a non-standard, periodic disclosure announcement.
2017-07-06 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 1% confidence The document is a press release dated July 05, 2017, announcing positive preclinical results for the drug candidate AsiDNA™. It details scientific findings, mentions upcoming regulatory filings ('we intend to file the phase I trial submission dossier to regulatory authorities by the end of 2017'), and provides company background and contact information. This content is characteristic of an initial announcement of scientific/clinical progress, which is typically categorized as an Earnings Release (ER) if it were tied to financial reporting, or more generally as a Regulatory Filing (RNS) if it's a broad announcement. However, given the focus on specific scientific milestones and the intent to file for a clinical trial, it functions as a key operational update for investors. Since it is not a full financial report (10-K, IR), a transcript (CT), or a formal management discussion (MDA), and it is a direct announcement of results rather than an announcement *about* a report (RPA), the most fitting category for a significant, non-financial operational update that impacts the company's future is often the general Regulatory Filings (RNS) or, if it contains key operational highlights, ER. Given the structure and content—announcing specific positive data points and future clinical plans—it strongly resembles an Earnings Release (ER) which often includes operational highlights outside of pure financial figures, or a general Regulatory Filing (RNS). Since it is a press release announcing specific operational/scientific progress, and RNS is the fallback for miscellaneous regulatory announcements, RNS is appropriate, but ER often covers key operational milestones announced via press release. Given the context of a biotech company announcing clinical progress, RNS is the safest general classification for non-standard filings, but since it is a major announcement, I will check if it fits better elsewhere. It is not a formal financial report, dividend notice, or management change. It is a scientific/operational update. I will classify it as RNS (Regulatory Filings) as it is a general regulatory announcement that doesn't fit the specific operational/financial codes.
2017-07-05 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Earnings Release Classification · 1% confidence The document is a press release dated July 5, 2017, announcing positive preclinical proof-of-concept results for the drug candidate AsiDNA™ administered systemically. It details scientific findings, future clinical plans (Phase I submission by end of 2017), and provides company background and contact information. This type of announcement, focusing on specific scientific or operational milestones rather than comprehensive periodic financial results (like 10-K or IR) or management changes, is characteristic of an Earnings Release (ER) or a general press release. Since it is a detailed announcement of results and future plans, but not the full quarterly/annual financial report itself, 'ER' (Earnings Release) is the most appropriate classification, as these releases often contain key operational and scientific updates alongside financial highlights, even if the financial highlights are minimal or absent in this specific excerpt. It is not a transcript (CT), a formal regulatory filing like 10-K, or a dedicated investor presentation (IP). Given the focus on announcing results, ER is the best fit among the options. FY 2017
2017-07-05 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Share Issue/Capital Change Classification · 1% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and announces that Onxeo successfully raised approximately 15 million euros through a private placement via an accelerated book-building process (an equity increase). This action directly relates to the company's fundraising and capital structure changes. This aligns perfectly with the definition for Capital/Financing Update (CAP). Although it is a press release, the core content is the financing event itself, not just the announcement of a report (which would suggest RPA or RNS).
2017-06-20 French
Communicated under the obligation to provide permanent information / Other communications
Share Issue/Capital Change Classification · 1% confidence The document is explicitly titled 'PRESS RELEASE' and announces that 'Onxeo successfully raises €15 Million with US and European investors' through a 'private placement via an accelerate book-build offering.' This content directly relates to fundraising, financing activities, and changes in capital structure. This aligns perfectly with the definition for Capital/Financing Update (CAP). Although it is a press release, the core subject matter is the financing event itself, not merely announcing the publication of a separate, detailed report (which would suggest RPA or RNS).
2017-06-20 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Share Issue/Capital Change Classification · 1% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and announces the launch of a capital increase ('augmentation de capital') through an accelerated book-building process. This action involves issuing new shares to raise funds for R&D and general financing. This directly relates to the company's fundraising and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). Although it is a press release, its core content is the financing event, not just the announcement of a report (RPA/RNS).
2017-06-19 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.